The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Subscribe To Our Newsletter & Stay Updated
